| Ytd | -29.90% | |
| 1y | 47.22% |
| Open | 11.16 | Prev Close | 11.25 | Low | 11.12 | High | 11.62 | Mkt Cap | 897.25M |
| Vol | 427.15K | Avg Vol | 1.23M | EPS | -1.47 | P/E | -7.65 | Forward P/E | 7.60 |
| Beta | 0.49 | Short Ratio | 9.36 | Inst. Own | 83.10% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 10.98 | 200-d Avg | 12.69 | 1yr Est | 23.70 |
PHAT News
Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT Management to host con
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and c
This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Confere
FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a
FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a
FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.18 per share versus the Za
FLORHAM PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),
Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., A
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report) has received a consensus recommendati
FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),
Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to Overweight from Eq
Top Wall Street analysts upgraded PHAT and PWR, while AGX was upgraded to Overweight with a $550 pri
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report) has earned a consensus recommendation
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference T
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.08 per share versus the Za
Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175
FLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),
FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),
During Monday's trading, 1214 companies set new 52-week lows.